Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): I--Utilization of cimetidine and cyclosporine A.
Cimetidine (CMT), cyclosporine A (CsA), interleukin 2 (IL 2), were used to characterize the anticancerous effect of a polyantigenic immunodulator (PAI). PAI consists of a mixture of inactivated bacteria and influenza virus in a peanut oil-arlacel A-aluminum monoesterate emulsion. Antitumoral activity was tested on Ehrlich's ascites tumor (EAT) implanted into Swiss-Webster (allogeneic) or C57BL/6J (syngeneic) mice. PAI antitumor activity was enhanced by CMT acting synergistically by reducing substantially the tumor growth and increasing the percentage of surviving mice, while CsA suppressed this activity. PAI or its individual components were able to induce significant lymphocyte blastogenesis in mouse (C57BL/6J)-spleen lymphocytes and IL-2 enhanced considerably this lymphoproliferative response. The results suggest that PAI acts at the level of cellular immunity.
Ríos-Olivares
E
E
Orraca
Z M
ZM
Carrasco-Canales
J A
JA
Alvarado
L
L
Marchand
A M
AM
Colón
J I
JI
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000276:immunology; D002927:Cimetidine / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL
D000276:Adjuvants, Immunologic; D003524:Cyclosporins; D007376:Interleukin-2; D002927:Cimetidine